Literature DB >> 19437382

[The cost of schizophrenia in Germany: a systematic review of the literature].

Alexander Konnopka1, Stefan Klingberg, Andreas Wittorf, Hans-Helmut König.   

Abstract

OBJECTIVE: The aim of this study was a systematic literature review of cost-of-illness studies for schizophrenia in Germany.
METHODS: We conducted a database search in Pubmed and PsychINFO. Cost data were inflated to the year 2007.
RESULTS: We finally included 11 studies in our review which show that schizophrenia causes societal cost of several billion Euros per year. After adjustment for inflation, costs per patient and year estimated between 1980 and 2002 tended to be relatively stable at around 14,000 to 18,000 Euro. Additionally, relatives are confronted with spending of 950 to 1,700 Euro due to the patients' disorder. Indirect costs are mainly due to early retirement or unemployment and amount to 25,000 to 30,000 Euro per patient when using the human capital approach. We found that changes in treatment settings and increasing costs of drug treatment seem to be reflected in published cost-of-illness studies.
CONCLUSIONS: When corrected for inflation, treatment cost per patient for schizophrenia show changes in their distribution over different cost sectors in the health care system but no substantial increases between 1980 and 2002.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19437382     DOI: 10.1055/s-0028-1090234

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  12 in total

Review 1.  Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis.

Authors:  Hendrik Müller; Sonja Laier; Andreas Bechdolf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-27       Impact factor: 5.270

2.  Evaluation of an integrated care program for schizophrenia: concept and study design.

Authors:  L Kerkemeyer; S Mostardt; J Biermann; J Wasem; A Neumann; A Walendzik; R Jahn; C Bartels; P Falkai; W Brannath; V Breunig-Lyriti; B Mester; J Timm; T Wobrock
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-06-07       Impact factor: 5.270

3.  Effectiveness and costs of flupentixol compared to other first- and second-generation antipsychotics in the treatment of schizophrenia.

Authors:  Tom Stargardt; Paraskevi Mavrogiorgou; Christian A Gericke; Georg Juckel
Journal:  Psychopharmacology (Berl)       Date:  2011-03-25       Impact factor: 4.530

4.  Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data.

Authors:  Simon Frey; Roland Linder; Georg Juckel; Tom Stargardt
Journal:  Eur J Health Econ       Date:  2013-02-19

5.  The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective.

Authors:  Jan Zeidler; Lara Slawik; Jochen Fleischmann; Wolfgang Greiner
Journal:  Health Econ Rev       Date:  2012-05-04

Review 6.  Genetics, cognition, and neurobiology of schizotypal personality: a review of the overlap with schizophrenia.

Authors:  Ulrich Ettinger; Inga Meyhöfer; Maria Steffens; Michael Wagner; Nikolaos Koutsouleris
Journal:  Front Psychiatry       Date:  2014-02-21       Impact factor: 4.157

7.  Evidence for Distinguishable Treatment Costs among Paranoid Schizophrenia and Schizoaffective Disorder.

Authors:  Dusan Hirjak; Achim Hochlehnert; Philipp Arthur Thomann; Katharina Maria Kubera; Knut Schnell
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

8.  Hospitalization rates and resource utilization of schizophrenic patients switched from oral antipsychotics to aripiprazole-depot in Germany.

Authors:  Christoph Potempa; Reinhard Rychlik
Journal:  Health Econ Rev       Date:  2018-11-23

9.  An Integrated Care Initiative to Improve Patient Outcome in Schizophrenia.

Authors:  Norbert Mayer-Amberg; Rainer Woltmann; Stefanie Walther
Journal:  Front Psychiatry       Date:  2016-01-08       Impact factor: 4.157

10.  Outpatient Psychotherapy Reduces Health-Care Costs: A Study of 22,294 Insurants over 5 Years.

Authors:  Uwe Altmann; Anna Zimmermann; Helmut A Kirchmann; Dietmar Kramer; Andrea Fembacher; Ellen Bruckmayer; Irmgard Pfaffinger; Fritz von Heymann; Emma Auch; Rolf Steyer; Bernhard M Strauss
Journal:  Front Psychiatry       Date:  2016-06-13       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.